1. Home
  2. GLUE vs TCI Comparison

GLUE vs TCI Comparison

Compare GLUE & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLUE
  • TCI
  • Stock Information
  • Founded
  • GLUE 2019
  • TCI 1983
  • Country
  • GLUE United States
  • TCI United States
  • Employees
  • GLUE N/A
  • TCI N/A
  • Industry
  • GLUE Biotechnology: Pharmaceutical Preparations
  • TCI Real Estate
  • Sector
  • GLUE Health Care
  • TCI Finance
  • Exchange
  • GLUE Nasdaq
  • TCI Nasdaq
  • Market Cap
  • GLUE 351.2M
  • TCI 357.8M
  • IPO Year
  • GLUE 2021
  • TCI N/A
  • Fundamental
  • Price
  • GLUE $4.80
  • TCI $45.60
  • Analyst Decision
  • GLUE Buy
  • TCI
  • Analyst Count
  • GLUE 2
  • TCI 0
  • Target Price
  • GLUE $13.50
  • TCI N/A
  • AVG Volume (30 Days)
  • GLUE 369.2K
  • TCI 1.8K
  • Earning Date
  • GLUE 08-07-2025
  • TCI 08-07-2025
  • Dividend Yield
  • GLUE N/A
  • TCI N/A
  • EPS Growth
  • GLUE N/A
  • TCI 11.20
  • EPS
  • GLUE 0.29
  • TCI 0.76
  • Revenue
  • GLUE $177,986,000.00
  • TCI $47,730,000.00
  • Revenue This Year
  • GLUE $83.76
  • TCI N/A
  • Revenue Next Year
  • GLUE N/A
  • TCI N/A
  • P/E Ratio
  • GLUE $16.32
  • TCI $61.66
  • Revenue Growth
  • GLUE 2990.57
  • TCI N/A
  • 52 Week Low
  • GLUE $3.50
  • TCI $25.50
  • 52 Week High
  • GLUE $12.40
  • TCI $48.00
  • Technical
  • Relative Strength Index (RSI)
  • GLUE 51.69
  • TCI 56.33
  • Support Level
  • GLUE $4.54
  • TCI $46.00
  • Resistance Level
  • GLUE $4.93
  • TCI $48.00
  • Average True Range (ATR)
  • GLUE 0.21
  • TCI 0.80
  • MACD
  • GLUE 0.06
  • TCI 0.05
  • Stochastic Oscillator
  • GLUE 81.43
  • TCI 67.90

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

Share on Social Networks: